| Steroid biosynthesis |
2.43 |
0.00e+0 |
19/20 (95%) |
MSMO1;DHCR24;SQLE;...
|
| Terpenoid backbone biosynthesis |
2.16 |
0.00e+0 |
18/22 (81.82%) |
HMGCS1;ACAT2;FDPS;...
|
| Citrate cycle (TCA cycle) |
2.06 |
0.00e+0 |
30/30 (100%) |
IDH1;FH;ACO1;...
|
| Pyrimidine metabolism |
2.01 |
2.47e-3 |
40/56 (71.43%) |
DPYD;CDA;NT5E;...
|
| Pyruvate metabolism |
1.98 |
1.97e-3 |
41/47 (87.23%) |
ACAT2;ALDH3A2;ADH1B;...
|
| Drug metabolism |
1.94 |
1.65e-3 |
78/151 (51.66%) |
DPYD;AOX1;ADH1B;...
|
| DNA replication |
1.93 |
1.41e-3 |
34/36 (94.44%) |
POLE2;MCM6;PCNA;...
|
| Valine, leucine and isoleucine degradation |
1.91 |
1.23e-3 |
42/48 (87.5%) |
HMGCS1;ACAT2;AOX1;...
|
| Tryptophan metabolism |
1.88 |
2.19e-3 |
35/42 (83.33%) |
ACAT2;AOX1;ALDH3A2;...
|
| Serotonergic synapse |
1.86 |
6.91e-3 |
97/114 (85.09%) |
GNAI1;GNG12;PRKCA;...
|
| Fatty acid degradation |
1.86 |
6.28e-3 |
40/43 (93.02%) |
ACAT2;ACSL1;ALDH3A2;...
|
| Biosynthesis of unsaturated fatty acids |
1.85 |
5.76e-3 |
21/27 (77.78%) |
FADS1;SCD;FADS2;...
|
| Metabolism of xenobiotics by cytochrome P450 |
1.78 |
9.87e-3 |
49/77 (63.64%) |
CBR3;ADH1B;MGST3;...
|
| Glyoxylate and dicarboxylate metabolism |
1.78 |
1.06e-2 |
23/30 (76.67%) |
ACAT2;ACAT1;SHMT1;...
|
| Propanoate metabolism |
1.73 |
2.17e-2 |
30/34 (88.24%) |
ACAT2;ACACA;ACAT1;...
|
| Long-term depression |
1.72 |
2.22e-2 |
55/60 (91.67%) |
GNAI1;PRKCA;GRIA2;...
|
| Peroxisome |
1.71 |
2.38e-2 |
72/82 (87.8%) |
ACSL1;IDH1;PHYH;...
|
| Regulation of lipolysis in adipocytes |
1.69 |
3.24e-2 |
52/55 (94.55%) |
GNAI1;IRS2;AKT3;...
|
| Synthesis and degradation of ketone bodies |
1.67 |
3.59e-2 |
9/10 (90%) |
HMGCS1;ACAT2;ACAT1
|
| Renin-angiotensin system |
1.66 |
3.85e-2 |
20/23 (86.96%) |
MME;ENPEP;CTSA;...
|
| Histidine metabolism |
1.66 |
3.67e-2 |
16/22 (72.73%) |
ALDH3A2;ALDH9A1;HAL;...
|
| alpha-Linolenic acid metabolism |
1.65 |
3.82e-2 |
17/25 (68%) |
FADS2;PLAAT3;PLA2G4A;...
|
| Glycolysis / Gluconeogenesis |
1.63 |
4.25e-2 |
56/67 (83.58%) |
PFKP;ALDH3A2;ADH1B;...
|
| Porphyrin and chlorophyll metabolism |
1.62 |
4.73e-2 |
23/43 (53.49%) |
BLVRA;PPOX;BLVRB;...
|
| Parkinson disease |
1.61 |
4.86e-2 |
176/249 (70.68%) |
GNAI1;TUBA1A;MAP3K5;...
|
| Glutamatergic synapse |
1.61 |
4.79e-2 |
97/114 (85.09%) |
GNAI1;SLC1A1;GNG12;...
|
| Viral myocarditis |
1.60 |
4.86e-2 |
53/60 (88.33%) |
CAV1;HLA-F;HLA-C;...
|
| Circadian entrainment |
1.60 |
4.69e-2 |
85/97 (87.63%) |
GNAI1;GNG12;PRKCA;...
|
| Lipid and atherosclerosis |
-1.59 |
4.35e-2 |
190/215 (88.37%) |
PPP3CC;RELA;VCAM1;...
|
| Basal transcription factors |
-1.63 |
3.38e-2 |
37/45 (82.22%) |
TAF4;TAF13;TAF7;...
|
| RNA transport |
-1.63 |
3.48e-2 |
128/186 (68.82%) |
ACIN1;TARDBP;EIF3B;...
|
| Th1 and Th2 cell differentiation |
-1.64 |
3.45e-2 |
80/92 (86.96%) |
CD247;IKBKB;JAK3;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.65 |
3.10e-2 |
79/89 (88.76%) |
CHUK;ALK;RPS6KB2;...
|
| Colorectal cancer |
-1.65 |
3.20e-2 |
84/86 (97.67%) |
EGF;PIK3CD;AKT2;...
|
| Hippo signaling pathway |
-1.68 |
2.34e-2 |
120/186 (64.52%) |
PPP2CB;GSK3B;FZD8;...
|
| T cell receptor signaling pathway |
-1.70 |
2.04e-2 |
93/104 (89.42%) |
PAK2;CD247;IKBKB;...
|
| Thyroid cancer |
-1.70 |
2.15e-2 |
36/37 (97.3%) |
NRAS;BAX;TFG;...
|
| Hepatitis B |
-1.71 |
2.10e-2 |
151/162 (93.21%) |
PIK3CD;AKT2;MAPK8;...
|
| Chronic myeloid leukemia |
-1.72 |
2.10e-2 |
72/76 (94.74%) |
PIK3CD;AKT2;CBL;...
|
| Inflammatory bowel disease |
-1.74 |
1.56e-2 |
58/65 (89.23%) |
IL17A;HLA-DPB1;IL18RAP;...
|
| ECM-receptor interaction |
-1.76 |
1.24e-2 |
80/88 (90.91%) |
GP5;TNN;AGRN;...
|
| Breast cancer |
-1.79 |
9.40e-3 |
119/147 (80.95%) |
GSK3B;TNFSF11;FZD8;...
|
| Osteoclast differentiation |
-1.84 |
6.79e-3 |
117/127 (92.13%) |
LILRB5;CHUK;NCF4;...
|
| Protein export |
-1.85 |
6.48e-3 |
17/23 (73.91%) |
SEC62;SRP72;SEC11A;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.85 |
7.13e-3 |
97/100 (97%) |
PIK3CD;AKT2;MAPK8;...
|
| Th17 cell differentiation |
-1.87 |
7.92e-3 |
95/107 (88.79%) |
IL2;MAPK8;JAK1;...
|
| NF-kappa B signaling pathway |
-1.87 |
8.91e-3 |
90/104 (86.54%) |
TRAF1;TICAM1;TRIM25;...
|
| Bladder cancer |
-1.88 |
1.02e-2 |
40/41 (97.56%) |
NRAS;DAPK3;MMP1;...
|
| Malaria |
-1.95 |
0.00e+0 |
44/50 (88%) |
CSF3;VCAM1;IFNG;...
|
| TNF signaling pathway |
-2.00 |
0.00e+0 |
103/112 (91.96%) |
RELA;VCAM1;VEGFD;...
|
| TGF-beta signaling pathway |
-2.06 |
0.00e+0 |
81/94 (86.17%) |
IFNG;SMAD6;E2F5;...
|
| IL-17 signaling pathway |
-2.13 |
0.00e+0 |
84/94 (89.36%) |
MAPK8;IL4;IL5;...
|
| Rheumatoid arthritis |
-2.18 |
0.00e+0 |
78/93 (83.87%) |
CTSK;IFNG;IL23A;...
|
| Spliceosome |
-2.54 |
0.00e+0 |
101/150 (67.33%) |
RBM22;SF3A1;PCBP1;...
|
